Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.
|Headquarters||New York, New York|
|Number of employees||51-200 employees|
Top 5 Recent Tweets
|January 19, 2021||urotoday||Implications of PSMA PET imaging for #ProstateCancer. A step towards personalized medicine. Presentation & discussi… https://t.co/3YvQj46lMA|
|January 19, 2021||StockTipRobot||Stock tip not found. Instead, just sell your human children and buy Progenics Pharmaceuticals Inc. $PGNX #money|
|January 18, 2021||urotoday||Applying #ArtificialIntelligence to PSMA-targeted PET #Imaging agent 18F-DCFPyL in #ProstateCancer: lecture & discu… https://t.co/XiCsuRqAUY|